AMGN vs NVO

Amgen and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $191B against $182B. Over the past year AMGN returned +59% against +1.5% for NVO.

Amgen and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
FigureAMGNNVO
Last close$440$47.19
Market cap$182B$191B
Trailing P/Elower is cheaper for the same earnings, not automatically better27.4n/a
Dividend yield2.2%n/a
1-year return+59%+1.5%
5-year return+113%+13%
Ryufin Smart Scoresector-relative, 1–109/109/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Amgen

Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.

AMGN overviewrevenue and segmentsvaluation

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.